{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T15:42:31Z","timestamp":1698507751961},"reference-count":20,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2007,4,29]],"date-time":"2007-04-29T00:00:00Z","timestamp":1177804800000},"content-version":"vor","delay-in-days":4045,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergy"],"published-print":{"date-parts":[[1996,4]]},"abstract":"<jats:p>Mizolastine is a new, nonsedating antihistamine providing satisfactory symptom relief in allergic rhinitis and urticaria. The purpose of this study was to use the wheal and flare skin reactions model to assess the maintenance of the pharmacodynamic effect of mizolastine, administered for 2 months. This double\u2010blind, parallel\u2010group study involved 60 atopic patients randomly allocated, after a 1\u2010week placebo run\u2010in, to once\u2010daily 10 mg mizolastine (<jats:italic>n<\/jats:italic>= 29) or placebo (<jats:italic>n<\/jats:italic>= 31) groups. Treatment continued for 8 weeks. Prick tests were performed in duplicate with histamine chlorhydrate (10mg\/ml), codeine phosphate (9%), and five increasing concentrations (1\u2013500 reactivity index\/ml) of standardized allergen extracts (grass pollen or mites) at days 0, 7, 28, 42, and 56. After 7 days of treatment, inhibition of histamine\u2010induced wheal was \u201076% and + 20%, respectively, with mizolastine and placebo (<jats:italic>P<\/jats:italic>= 0.0001), in comparison with baseline; inhibition of flare was \u2010 86% and + 50%, respectively, with mizolastine and placebo (<jats:italic>P =<\/jats:italic> 0.0001). Suppression was maintained to a similar extent throughout the study. Results were consistent between histamine\u2010, codeine\u2010, and allergen\u2010induced tests. Safety was satisfactory in both groups. This study confirms mizolastine as a potent antihistamine which does not induce subsensitivity when taken for 8 weeks, and which can be safely recommended in allergic conditions.<\/jats:p>","DOI":"10.1111\/j.1398-9995.1996.tb04601.x","type":"journal-article","created":{"date-parts":[[2008,4,30]],"date-time":"2008-04-30T10:34:19Z","timestamp":1209551659000},"page":"251-256","source":"Crossref","is-referenced-by-count":0,"title":["Lack of subsensitivitvy to mizolastine over 8\u2010week treatment"],"prefix":"10.1111","volume":"51","author":[{"given":"J.","family":"Bousquet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Chanal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Murrieta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Stalla\u2010Bourdillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,4,29]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/jid.1950.61","article-title":"Development of refractory condition of skin towards antihistamine drugs after antihistaminic therapy as determined by histamine iontophoresis","volume":"15","author":"Monash S.","year":"1950","journal-title":"J Invest Dermatol"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-8707(51)90033-0"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(85)90811-5"},{"key":"e_1_2_1_5_2","first-page":"341","article-title":"Chronic chlorpheniramine therapy: subsensitivity, drug metabolism, and compliance","volume":"59","author":"Bantz EW","year":"1987","journal-title":"Ann Allergy"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(85)90813-9"},{"key":"e_1_2_1_7_2","first-page":"253","article-title":"Suppression of histamine\u2010induced wheal response by loratadine (SCH 29851) over 28 days in man","volume":"57","author":"Roman IJ","year":"1986","journal-title":"Ann Allergy"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(05)80072-7"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(88)90145-5"},{"key":"e_1_2_1_10_2","first-page":"111","article-title":"The skin as a target organ for the investigation of antiallergic drugs: comparison between cetirizine and terfenadine","volume":"184","author":"Rihoux JP","year":"1992","journal-title":"Pharmacol Treat"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(89)90358-8"},{"key":"e_1_2_1_12_2","first-page":"459","article-title":"Comparative wheal and flare study of mizolastine versus terfenadine, cetirizine, loratddine and placebo in healthy volunteers","volume":"40","author":"Rosenzweig P.","year":"1995","journal-title":"Br J Clin Pharmacol"},{"issue":"16","key":"e_1_2_1_13_2","first-page":"30","article-title":"Mizolastine's effects on psychomotor and actual driving performance in healthy volunteers after single 5, 10, 20 and 40 mg doses vs. clemastine 2 mg and placebo","volume":"48","author":"Vuurman P.","year":"1993","journal-title":"Eur J Allergy Clin Immunol"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00191164"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(90)93512-O"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199400920-00006"},{"key":"e_1_2_1_17_2","first-page":"135","article-title":"Pharmacodynamics and pharmacokinetics of mizolastine (SL 85.0324), a new nonsedative H1 antihistamine","volume":"69","author":"Rosenzweig P.","year":"1992","journal-title":"Ann Allergy"},{"issue":"12","key":"e_1_2_1_18_2","first-page":"177","article-title":"A double\u2010blind comparative study of mizolastine 10 mg and placebo in the treatment of seasonal allergic rhinoconjunctivitis in adult patients","volume":"47","author":"Stern MA","year":"1992","journal-title":"Eur J Allergy Clin Immunol"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(90)90091-H"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-110-4-304"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1991.tb03913.x"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1398-9995.1996.tb04601.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1398-9995.1996.tb04601.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T13:45:23Z","timestamp":1698414323000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1398-9995.1996.tb04601.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,4]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1996,4]]}},"alternative-id":["10.1111\/j.1398-9995.1996.tb04601.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1398-9995.1996.tb04601.x","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,4]]}}}